갑상선암 진단 시장 - 전략적 인사이트와 예측(2026-2035년)

The Thyroid Cancer Diagnostics Market is set to reach USD 10.54 billion in 2035, growing at a CAGR of 9.3 % from USD 4.75 billion in 2026.

The thyroid cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward precision oncology, molecular risk stratification, and personalized treatment strategies. The market's evolution is characterized by the growing recognition that accurate diagnosis and molecular characterization are essential for optimizing patient management, reducing unnecessary surgeries, and enabling targeted therapy selection. The convergence of advanced molecular technologies, including next-generation sequencing, gene expression profiling, and liquid biopsy, is enabling faster, more accurate, and increasingly comprehensive thyroid cancer detection and risk assessment. Healthcare systems worldwide are expanding diagnostic capabilities as thyroid cancer incidence continues to rise globally. The market is witnessing significant investment in molecular diagnostic panels, AI-assisted cytopathology, and companion diagnostics, positioning thyroid cancer diagnostics as a critical component of endocrine oncology and precision medicine.

Market Drivers

• The rising global thyroid cancer incidence represents the primary driver for the thyroid cancer diagnostics market. Increasing disease burden creates demand for early diagnosis, advanced molecular testing, and accurate biomarker-based precision oncology solutions worldwide. Healthcare providers are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in thyroid cancer diagnostic utilization. The growing adoption of next-generation sequencing and genomic profiling is further accelerating market growth through improved diagnostic accuracy, personalized treatment selection, and clinical decision-making across healthcare systems. Precision medicine requires comprehensive genomic characterization to guide targeted therapy decisions. Healthcare providers are expanding molecular testing programs to support personalized treatment strategies. Diagnostic manufacturers are developing genomic profiling solutions to capture growing demand. Increasing awareness of early cancer detection encourages routine thyroid screening, boosting utilization of imaging, cytopathology, and molecular diagnostic technologies globally. Public health campaigns are increasing screening participation and early detection. Healthcare systems are expanding access to diagnostic services and technologies. Continuous advancements in digital pathology, artificial intelligence, and companion diagnostics enhance workflow efficiency, diagnostic confidence, and patient management outcomes. Technological innovation is improving diagnostic accuracy and reducing unnecessary procedures. Healthcare providers are adopting AI-assisted diagnostics to improve efficiency and consistency. Diagnostic manufacturers are developing advanced platforms to capture growing demand.

Market Restraints

• High costs of molecular diagnostic tests and genomic sequencing limit widespread adoption, particularly across low- and middle-income healthcare markets. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited reimbursement coverage for advanced genomic diagnostics restricts patient access and slows adoption of precision oncology technologies in several regions. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Shortage of skilled molecular pathologists and specialized laboratory professionals affects diagnostic capacity, interpretation accuracy, and implementation of advanced testing. The limited availability of specialized personnel reduces diagnostic capacity and scalability. Stringent regulatory approval requirements increase development timelines, compliance costs, and commercialization challenges for innovative thyroid diagnostic technologies.

Technology and Modality Insights

• The technology landscape is characterized by the growing importance of molecular diagnostics, genomic profiling, and AI-enabled platforms. Fine needle aspiration remains the gold standard for initial evaluation of suspicious thyroid nodules due to its high diagnostic accuracy and minimally invasive nature. Immunohistochemistry supports tumor characterization and differential diagnosis. PCR-based assays enable mutation detection. NGS is experiencing rapid growth through comprehensive genomic profiling. Gene expression profiling is increasingly utilized to improve risk stratification and reduce unnecessary thyroid surgeries. The segment analysis reveals that imaging diagnostics account for a significant share as ultrasound remains the primary tool for thyroid nodule evaluation and risk assessment. Cytopathology continues to play a central role through FNA-based diagnosis. Molecular diagnostics represent the fastest-growing segment owing to increasing adoption of genomic profiling and precision oncology. BRAF mutation testing represents the largest biomarker segment because of its strong association with papillary thyroid carcinoma and therapeutic decision-making. RAS mutation analysis supports diagnosis of follicular-patterned thyroid lesions. RET gene alteration testing is becoming increasingly important for precision oncology and targeted therapy selection. Thyroid nodule evaluation represents a critical application, with cancer diagnosis and risk stratification experiencing rapid growth. Hospitals and diagnostic laboratories represent the leading end-user segments, with cancer centers and academic research institutes expanding diagnostic capabilities. The integration of AI is becoming increasingly important as AI improves diagnostic efficiency, workflow automation, and interpretation consistency.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized molecular, endocrine, and precision oncology providers. Roche develops molecular diagnostics, companion diagnostics, tissue diagnostics, and precision oncology solutions supporting thyroid cancer diagnosis and targeted treatment selection. Thermo Fisher Scientific provides PCR technologies, sequencing platforms, molecular diagnostics, and precision oncology solutions supporting thyroid cancer testing. Danaher offers genomics technologies, molecular diagnostics, laboratory automation, and precision medicine solutions supporting oncology diagnostics. Agilent specializes in pathology solutions, immunohistochemistry assays, genomic technologies, and companion diagnostics supporting thyroid cancer diagnosis. Illumina is a leading provider of NGS platforms enabling comprehensive genomic profiling and biomarker discovery for thyroid cancer. QIAGEN develops molecular diagnostic assays, PCR technologies, sample preparation systems, and companion diagnostics supporting personalized oncology. Abbott provides immunoassays, clinical chemistry systems, molecular diagnostics, and laboratory testing solutions supporting oncology diagnostics. Siemens Healthineers develops advanced imaging systems, laboratory diagnostics, AI-enabled healthcare technologies, and digital diagnostic solutions. Companies are pursuing product portfolio expansion through innovation in molecular diagnostic panels, liquid biopsy, and AI-enabled platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding its liquid biopsy portfolio with enhanced genomic profiling capabilities for solid tumors. Veracyte advanced its genomic testing portfolio through continued expansion of molecular diagnostic applications for thyroid disease. Roche introduced enhanced companion diagnostic solutions supporting precision oncology. Illumina expanded NGS applications for comprehensive oncology genomic profiling.

Short Conclusion

• The thyroid cancer diagnostics market is positioned for sustained growth driven by the convergence of rising disease incidence, technological innovation, and precision medicine. The transition from conventional diagnostic approaches toward integrated molecular and genomic strategies represents a fundamental shift in endocrine oncology. While challenges related to high costs, reimbursement limitations, and workforce shortages persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with thyroid cancer diagnostics evolving into a critical component of precision oncology, supporting early detection, risk stratification, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Thyroid Cancer Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Overview
• 3.3 Disease Evolution and Diagnostic Landscape
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Prevalence Analysis
• 3.8 Diagnosed Patient Population Analysis
• 3.9 Thyroid Cancer Diagnostic Testing Volume Analysis
• 3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Molecular Diagnostic Panels
• 6.4 Artificial Intelligence in Thyroid Nodule Assessment
• 6.5 Genomic Biomarker Development
• 6.6 Liquid Biopsy Technologies
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Thyroid Cancer Diagnostics Market Landscape Analysis

• 8.1 Analysis by Diagnostic Modality
  • 8.1.1 Imaging Diagnostics
  • 8.1.2 Cytopathology
  • 8.1.3 Molecular Diagnostics
  • 8.1.4 Histopathology
• 8.2 Analysis by Technology
  • 8.2.1 Fine Needle Aspiration (FNA)
  • 8.2.2 Immunohistochemistry (IHC)
  • 8.2.3 Polymerase Chain Reaction (PCR)
  • 8.2.4 Next-Generation Sequencing (NGS)
  • 8.2.5 Gene Expression Profiling
• 8.3 Analysis by Biomarker
  • 8.3.1 BRAF Mutation
  • 8.3.2 RAS Mutation
  • 8.3.3 RET Gene Alterations
  • 8.3.4 TERT Promoter Mutation
  • 8.3.5 Other Biomarkers
• 8.4 Analysis by Clinical Application
  • 8.4.1 Thyroid Nodule Evaluation
  • 8.4.2 Cancer Diagnosis
  • 8.4.3 Risk Stratification
  • 8.4.4 Treatment Selection
  • 8.4.5 Disease Monitoring

9. Global Thyroid Cancer Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software
• 9.2 By Technology
  • 9.2.1 Fine Needle Aspiration (FNA)
  • 9.2.2 Immunohistochemistry (IHC)
  • 9.2.3 Polymerase Chain Reaction (PCR)
  • 9.2.4 Next-Generation Sequencing (NGS)
  • 9.2.5 Gene Expression Profiling
  • 9.2.6 Other Technologies
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Cancer Centers
  • 9.3.4 Academic & Research Institutes

10. Global Thyroid Cancer Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Thyroid Cancer Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Thermo Fisher Scientific Inc.
  • 13.2.1 Company Overview
  • 13.2.2 Financials
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Developments
• 13.3 Danaher Corporation
  • 13.3.1 Company Overview
  • 13.3.2 Financials
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Developments
• 13.4 Agilent Technologies, Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Financials
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Developments
• 13.5 Illumina, Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Financials
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Developments
• 13.6 QIAGEN N.V.
  • 13.6.1 Company Overview
  • 13.6.2 Financials
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Developments
• 13.7 Abbott Laboratories
  • 13.7.1 Company Overview
  • 13.7.2 Financials
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Developments
• 13.8 Siemens Healthineers AG
  • 13.8.1 Company Overview
  • 13.8.2 Financials
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Developments
• 13.9 Bio-Rad Laboratories, Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Financials
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Developments
• 13.10 bioMerieux
  • 13.10.1 Company Overview
  • 13.10.2 Financials
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Developments
• 13.11 Veracyte, Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Financials
  • 13.11.3 Product Portfolio
  • 13.11.4 Recent Developments
• 13.12 Exact Sciences Corporation
  • 13.12.1 Company Overview
  • 13.12.2 Financials
  • 13.12.3 Product Portfolio
  • 13.12.4 Recent Developments
• 13.13 Guardant Health, Inc.
  • 13.13.1 Company Overview
  • 13.13.2 Financials
  • 13.13.3 Product Portfolio
  • 13.13.4 Recent Developments
• 13.14 Leica Biosystems
  • 13.14.1 Company Overview
  • 13.14.2 Financials
  • 13.14.3 Product Portfolio
  • 13.14.4 Recent Developments
• 13.15 Fujifilm Holdings Corporation
  • 13.15.1 Company Overview
  • 13.15.2 Financials
  • 13.15.3 Product Portfolio
  • 13.15.4 Recent Developments

14. Global Thyroid Cancer Diagnostics Market Commercial Forecast Analysis

• 14.1 Fine Needle Aspiration (FNA)-Based Diagnostics
• 14.2 Molecular Diagnostic Panels
• 14.3 Gene Expression Classifier Tests
• 14.4 Next-Generation Sequencing (NGS)-Based Tests
• 14.5 Immunohistochemistry (IHC)-Based Diagnostics
• 14.6 Liquid Biopsy Tests
• 14.7 Imaging Diagnostics

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends